Morgan Stanley Maintains Overweight on Dyne Therapeutics, Lowers Price Target to $36
Benzinga Newsdesk 1 month ago
Analyst RatingsNewsPrice Target
Morgan Stanley analyst Michael Ulz maintains Dyne Therapeutics (NASDAQ:DYN) with a Overweight and lowers the price target from $45 to $36.
Morgan Stanley analyst Michael Ulz maintains Dyne Therapeutics (NASDAQ:DYN) with a Overweight and lowers the price target from $45 to $36.